<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Atherosclerosis</journal-id>
      <journal-title-group>
        <journal-title>Atherosclerosis</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0021-9150</issn>
      <issn pub-type="epub">1879-1484</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3146704</article-id>
      <article-id pub-id-type="pmid">21481392</article-id>
      <article-id pub-id-type="publisher-id">ATH11917</article-id>
      <article-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.03.015</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Interleukin 18 and coronary heart disease: Prospective study and systematic review</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Jefferis</surname>
            <given-names>Barbara J.M.H.</given-names>
          </name>
          <email>B.jefferis@ucl.ac.uk</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
          <xref rid="cor0005" ref-type="corresp">⁎</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Papacosta</surname>
            <given-names>Olia</given-names>
          </name>
          <email>O.papacosta@ucl.ac.uk</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Owen</surname>
            <given-names>Christopher G.</given-names>
          </name>
          <email>c.owen@sgul.ac.u</email>
          <xref rid="aff0010" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wannamethee</surname>
            <given-names>S. Goya</given-names>
          </name>
          <email>G.wannamethee@ucl.ac.uk</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Humphries</surname>
            <given-names>Steve E.</given-names>
          </name>
          <email>s.humphries@ucl.ac.uk</email>
          <xref rid="aff0015" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Woodward</surname>
            <given-names>Mark</given-names>
          </name>
          <email>markw@georgeinstitute.org.au</email>
          <xref rid="aff0020" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lennon</surname>
            <given-names>Lucy T.</given-names>
          </name>
          <email>l.lennon@ucl.ac.uk</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thomson</surname>
            <given-names>Andrew</given-names>
          </name>
          <email>a.thomson@ucl.ac.uk</email>
          <xref rid="aff0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Welsh</surname>
            <given-names>Paul</given-names>
          </name>
          <email>P.welsh@clinmed.gla.ac.uk</email>
          <xref rid="aff0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rumley</surname>
            <given-names>Ann</given-names>
          </name>
          <email>Ar4a@clinmed.gla.ac.uk</email>
          <xref rid="aff0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lowe</surname>
            <given-names>Gordon D.O.</given-names>
          </name>
          <email>Gdlowe@clinmed.gla.ac.uk</email>
          <xref rid="aff0025" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Whincup</surname>
            <given-names>Peter H.</given-names>
          </name>
          <email>p.whincup@sgul.ac.uk</email>
          <xref rid="aff0010" ref-type="aff">b</xref>
        </contrib>
      </contrib-group>
      <aff id="aff0005"><label>a</label>Department of Primary Care and Population Health, University College London, Rowland Hill St., London NW3 2PF, UK</aff>
      <aff id="aff0010"><label>b</label>Division of Population Health Sciences, and Education St George's, University of London, Cranmer Terrace, London SW17 0RE, UK</aff>
      <aff id="aff0015"><label>c</label>Department of Cardiovascular Medicine, UCL Division of Medicine, Cardiovascular Genetics, BHF Laboratories, Rayne Building, UCL, 5 University Street, London WC1E 6JJ, UK</aff>
      <aff id="aff0020"><label>d</label>Professorial Unit, The George Institute for Global Health, PO Box M201, Missenden Rd., NSW 2050, Australia</aff>
      <aff id="aff0025"><label>e</label>Division of Cardiovascular and Medical Sciences, University of Glasgow, Royal Infirmary, Room 28, Level 4, Walton Building, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 OSF, UK</aff>
      <author-notes>
        <corresp id="cor0005"><label>⁎</label>Corresponding author. Tel.: +44 2078302239; fax: +44 2077941224. <email>B.jefferis@ucl.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2011</year>
      </pub-date>
      <volume>217</volume>
      <issue>1</issue>
      <fpage>227</fpage>
      <lpage>233</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>1</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>2</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>9</day>
          <month>3</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ireland Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ireland Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Aim</title>
          <p>Previous studies suggest that circulating levels of interleukin-18 (IL-18) may be prospectively related to risk of coronary heart disease (CHD) in the general population. We report new data from the largest prospective study to date, which are combined with data from all published prospective studies in a meta-analysis.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>We measured baseline IL-18 levels in stored serum samples of subjects from a case–control study nested within a prospective study of 5661 men aged 40–59 years recruited from general practices in 18 British towns in 1978–1980 and followed-up for up to 16 years (median time to event 8.4 years) for fatal CHD and non-fatal myocardial infarction (595 cases, 1238 controls).</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>IL-18 concentrations were strongly related to cigarette smoking, triglyceride, HDL-cholesterol (inversely) and to circulating levels of several inflammatory and haemostatic markers. Men in the top third of baseline IL-18 levels had an age-adjusted odds ratio (OR) for CHD of 1.55 (95% CI 1.21, 1.98) compared with those in the lowest third; this was reduced to 1.30 (95% CI 0.99, 1.69) after additional adjustment for vascular risk factors and 1.12 (95% CI 0.84, 1.49) after further adjustment for CRP and IL-6. In meta-analyses of CVD, associations (or effect sizes) were consistent between studies; RRs were 1.63 (95% CI 1.46, 1.82) after age adjustment, 1.39 (95% CI 1.24, 1.55) after additional risk factor adjustment and 1.34 (95% CI 1.17, 1.54) after additional adjustment for inflammatory markers.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>Circulating IL-18 is prospectively and independently associated with CVD risk.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Key words</title>
        <kwd>Coronary heart disease</kwd>
        <kwd>Epidemiology</kwd>
        <kwd>Interleukin-18</kwd>
        <kwd>Cohort</kwd>
        <kwd>Meta-analysis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Atherosclerosis includes an important inflammatory component <xref rid="bib0005" ref-type="bibr">[1]</xref>; a substantial body of evidence demonstrates prospective associations between circulating acute-phase reactant proteins (particularly C-reactive protein [CRP] and fibrinogen) and coronary heart disease (CHD) risk <xref rid="bib0010 bib0015" ref-type="bibr">[2,3]</xref>. More recently, growing evidence suggests that levels of circulating pro-inflammatory cytokines, particularly interleukin-6 (IL-6), are prospectively related to CHD risk <xref rid="bib0020" ref-type="bibr">[4]</xref>. However, evidence about the influence of circulating levels of other pro-inflammatory cytokines is more limited.</p>
    <p>Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine which plays an important role in the inflammatory cascade <xref rid="bib0025" ref-type="bibr">[5]</xref>. Some evidence suggests that its expression may be related to atherosclerotic plaque progression and vulnerability <xref rid="bib0030 bib0035" ref-type="bibr">[6,7]</xref>. Circulating concentrations of IL-18 have been prospectively related to vascular events in patients with stable and unstable angina <xref rid="bib0040" ref-type="bibr">[8]</xref> or pre-existing CHD <xref rid="bib0045 bib0050" ref-type="bibr">[9,10]</xref> and, more recently in nested case–control studies carried out within a population-based studies of healthy adults <xref rid="bib0055 bib0060 bib0065 bib0070" ref-type="bibr">[11–14]</xref>. In order to clarify the strength and independence of this relationship further, we report here on the relationship between IL-18 and CHD risk in a large prospective study with considerably more events than in previous studies: a nested case–control study of middle-aged British men, nested within a large prospective study (the British Regional Heart Study), in which we have previously reported data on the relations of CRP and IL-6 to CHD <xref rid="bib0020 bib0075" ref-type="bibr">[4,15]</xref>. To place our results in context, we have performed a systematic review and meta-analysis of all published prospective studies examining the relationship of IL-18 and CHD, also correcting for regression dilution bias.</p>
    <sec sec-type="methods" id="sec0005">
      <label>1</label>
      <title>Methods</title>
      <sec id="sec0010">
        <label>1.1</label>
        <title>British Regional Heart Study</title>
        <p>In 1978–1980, 7735 men aged 40–59 years were randomly selected from general practice registers in each of 24 British towns and invited to take part in the British Regional Heart Study (response rate 78%). Nurses administered questionnaires, made physical measurements, recorded an electrocardiogram (ECG) and collected non-fasting venous blood samples; in 5661 men in 18 of the study towns, serum was stored at −20 °C for subsequent analysis <xref rid="bib0080" ref-type="bibr">[16]</xref>. Pre-existing CHD was defined on the basis of a history of a doctor diagnosis of CHD, a positive history of angina or possible MI on the Rose (WHO) chest pain questionnaire or an ECG consistent with definite or possible CHD. All men were monitored subsequently for all-cause mortality and for cardiovascular morbidity, with a follow up loss of &lt;1% <xref rid="bib0085" ref-type="bibr">[17]</xref>. Fatal CHD cases were ascertained through National Health Service Central Registers on the basis of a death certificate with ICD-9 codes 410-414. The diagnosis of non-fatal myocardial infarction (MI) was based on reports from general practitioners, supplemented by regular reviews of general practice records, and diagnosed in accordance with World Health Organisation criteria <xref rid="bib0085" ref-type="bibr">[17]</xref>. A nested case–control study was established, based on all 643 CHD cases (279 CHD deaths and 364 cases of non-fatal MI) occurring between 1978 and 1995 and a total of 1278 controls (2 per case) “frequency matched” to cases on town of residence and age in 5-year bands was randomly selected from among men who had survived to the end of the study period (31/12/1995) free from incident CHD (the maximum follow-up time was 16 years and among the cases, the median time to event was 8.4 years). Serum samples were available for 595 of these cases and 1238 controls for IL-18 measurements to be carried out in 2004–2005. A sub-sample of 158 men had fasting serum samples drawn in both 1996 and 2000, and these were analysed for IL-18, in 2004–2005 in the same laboratory using the same methods <xref rid="bib0020" ref-type="bibr">[4]</xref>, in order to correct associations for regression dilution bias.</p>
      </sec>
      <sec id="sec0015">
        <label>1.2</label>
        <title>Laboratory methods</title>
        <p>Serum concentrations of IL-18 and IL-6 were assayed using enzyme immunoassays (R and D Systems, Oxford, UK) by laboratory personnel who were blind to the case–control status of samples. The intra- and inter-assay coefficients of variation for IL-18 were 5.6% and 10.4% respectively. CRP, serum amyloid A (SAA), intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin, P-selectin, von Willebrand factor (vWF), fibrin-D dimer and tissue plasminogen activator (t-PA) antigen were assayed as previously reported <xref rid="bib0075 bib0090 bib0095 bib0100 bib0105" ref-type="bibr">[15,18–21]</xref>.</p>
      </sec>
      <sec id="sec0020">
        <label>1.3</label>
        <title>Statistical analysis</title>
        <p>We pre-specified case–control analyses by thirds of IL-18 values in controls. Unmatched stratified logistic regression was fitted using unconditional maximum likelihood methods (SAS version 8.1). Models were fitted adjusted for (i) age (model 1), (ii) additionally for cigarette smoking (model 2), (iii) additionally for other established cardiovascular risk factors (blood pressure, total cholesterol, HDL cholesterol, body mass index [as continuous covariates], history of diabetes, history of CHD, social class and usual physical activity [as categorical covariates]) (model 3) and (iv) additionally for other inflammatory markers (IL-6 and C-reactive protein [continuous covariates, log transformed because of skewed distribution]) (model 4). Rosner's method for univariate models was used to calculate regression dilution ratios (RDRs) on a subset of men with repeated IL-18 measurements, using a linear regression model of the repeat measurement predicted by the first measurement <xref rid="bib0110" ref-type="bibr">[22]</xref>.</p>
      </sec>
      <sec id="sec0025">
        <label>1.4</label>
        <title>Systematic review</title>
        <p>A systematic review of all papers, letters, abstracts and review articles reporting on prospective associations between circulating interleukin-18 levels and CHD risk was conducted according to PRISMA guidelines. Relevant studies published between 1945 (Web of Science), 1970 (PubMed), 1974 (Embase) and October 2009 were identified from databases, by scanning reference lists and review articles and consulting experts in the field. Additionally, studies were sought using a combined text word and MESH/subject heading (for PubMed and Embase only) using the search strategy detailed in <xref rid="sec0070" ref-type="sec">Web Table 1</xref>. The review was restricted to studies carried out on human subjects and written in the English language. Studies eligible for inclusion in the current review included prospective cohort studies or nested case–control studies based on approximately general populations (where participants were not selected on the basis of pre-existing disease) and prospective studies of patients with pre-existing coronary artery disease (CAD). Populations defined using other criteria (for example, pre-existing diabetes or metabolic syndrome) were excluded. Studies had to include at least one year of follow-up for CHD events following baseline IL-18 measurements. Relevant CHD events included fatal CHD, non-fatal CHD or all CHD (fatal and non-fatal). Studies including CHD and stroke outcome in a combined “cardiovascular disease” end point were included, although a sub-analysis was conducted to check for differences in the associations between IL-18 and CHD and CVD endpoints. Data were extracted by two researchers in accordance with a pre-specified fixed protocol; discrepancies were resolved by discussion. Odds ratios (ORs) or hazard ratios (HRs) providing estimates of relative risk (RR) for CHD for the highest third of the control IL-18 distribution compared with the lowest third were sought, in models adjusted for: (i) age (and gender where appropriate) (model 1), (ii) age and established cardiovascular risk factors (particularly blood lipids, cigarette smoking, blood pressure, diabetes) (model 2) and (iii) age, established cardiovascular risk factors and other inflammatory markers (IL-6 and C-reactive protein) (model 3). If estimates could not be obtained from published reports, they were sought directly from study authors, with supplementary descriptive data as required.</p>
      </sec>
      <sec id="sec0030">
        <label>1.5</label>
        <title>Statistical analysis</title>
        <p>The meta-analysis was carried out using STATA 10. Estimates of log ORs or log HRs for different studies were combined using an inverse-variance weighted average in a fixed effects model: fixed effects were chosen over random effects because we did not have reason to expect different magnitude of results between studies. Between-study heterogeneity was assessed using the <italic>I</italic><sup>2</sup> statistic. Funnel plots were examined and tests described by Begg <xref rid="bib0115" ref-type="bibr">[23]</xref> and Egger <xref rid="bib0120" ref-type="bibr">[24]</xref> for small study bias were also performed. Pre-specified sensitivity analyses were undertaken using metaregression to investigate heterogeneity between studies with (i) CVD endpoints (combined CHD and other cardiovascular endpoints) compared to CHD and (ii) studies of approximately general populations compared with studies of patients with CAD.</p>
      </sec>
    </sec>
    <sec id="sec0035">
      <label>2</label>
      <title>Results</title>
      <sec id="sec0040">
        <label>2.1</label>
        <title>British Regional Heart Study</title>
        <p>Established vascular risk factors showed highly significant differences between cases and controls in the expected directions (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Geometric mean IL-18 levels were higher among cases than controls (percentage difference 9.0%, 95% CI 4.0–14.0%, <italic>p</italic> &lt;= 0.001). Baseline IL-18 levels in the control population were strongly related to cigarette smoking, triglyceride, HDL-cholesterol (inversely), acute phase proteins (CRP, SAA), IL-6, cellular adhesion molecules (ICAM-1, VCAM-1, E-selectin, P-selectin) and with haemostatic variables (vWF, fibrin D-dimer and t-PA). IL-18 levels were weakly related to diastolic BP, but were not appreciably related to age, BMI, total cholesterol, physical activity or to other established CHD risk factors (<xref rid="tbl0010" ref-type="table">Table 2</xref>). In a comparison of men in the top third compared with those in the bottom third of baseline IL-18 levels, the age-adjusted OR for CHD was 1.55 (95% CI 1.21, 1.98) (<xref rid="tbl0015" ref-type="table">Table 3</xref>). Adjustment for cigarette smoking slightly attenuated this OR, while additional adjustment for other vascular risk factors reduced the OR to 1.30 (95% CI 0.99, 1.69). Additional adjustment for CRP and IL-6 reduced the OR to 1.12 (95% CI 0.81, 1.55). In the last adjusted model, the OR for CVD for a doubling in CRP was 1.23 (95% CI 1.13, 1.33) and 1.15 (95% CI 1.00, 1.33) for a doubling in IL-6 (data not presented). Repeating the analysis excluding men with established CHD had little material impact on the results (<xref rid="tbl0015" ref-type="table">Table 3</xref>). An RDR of 0.71 (95% CI 0.61, 0.81) was calculated for the 158 men with IL-18 levels measured 4 years apart <xref rid="bib0125" ref-type="bibr">[25]</xref>. The OR of CHD among men in the top third of IL-18 compared with the lowest third, adjusted for age and vascular risk factors, increased from 1.30 (95% CI 0.99, 1.69) to 1.45 (95% CI 0.99, 2.09) after correction for regression dilution.</p>
      </sec>
      <sec id="sec0045">
        <label>2.2</label>
        <title>Meta-analysis</title>
        <p>From 458 studies identified, eleven relevant prospective studies (flow diagram, <xref rid="sec0070" ref-type="sec">Web Fig. 1</xref>), plus the BRHS were selected for the meta-analysis. Of the twelve included, eight were based on approximately general populations <xref rid="bib0055 bib0060 bib0065 bib0070 bib0130 bib0135 bib0140" ref-type="bibr">[11–14,26–28]</xref> and four on patients with CAD or at high risk of CHD <xref rid="bib0045 bib0050 bib0145 bib0150" ref-type="bibr">[9,10,29,30]</xref>; in all, these studies included a total of 3047 CVD cases and 11,071 control individuals (<xref rid="sec0070" ref-type="sec">Web Table 2</xref>). We were able to obtain relevant estimates for models 1 and 2 for all twelve studies and for model 3 for eleven studies (<xref rid="sec0070" ref-type="sec">Web Table 3</xref>). In nine studies the outcome was CHD and in the other three CHD was combined with other cardiovascular disease (CVD) e.g. stroke, and reported here as CVD. All studies except one <xref rid="bib0130" ref-type="bibr">[26]</xref> used ELISAs produced by one of two manufacturers. Estimates of the age-adjusted ORs and HRs (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>) showed little evidence of heterogeneity between studies (<italic>I</italic><sup>2</sup>, 12%, <italic>p</italic> = 0.327); there was no strong evidence of bias (examining the funnel plot for asymmetry and Egger test, <italic>p</italic> = 0.108; Begg test, <italic>p</italic> = 0.451, <xref rid="sec0070" ref-type="sec">Web Fig. 2</xref>). The age and gender adjusted RR of CVD (for the highest third of IL-18 compared with the lowest third of IL-18) in a fixed-effect meta-analysis was 1.64 (95% CI 1.48, 1.83). Adjustment for established cardiovascular risk factors reduced the RR to 1.35 (95% CI 1.25, 1.51); additional adjustment for inflammatory markers (CRP and IL-6) somewhat reduced the RR to 1.34 (95% CI 1.17, 1.53), although the increase in RR remained statistically significant (<xref rid="sec0070" ref-type="sec">Web Fig. 3</xref>). In age-adjusted analyses, RR estimates in approximately general populations (1.55 [95% CI 1.36, 1.77]) and patients with CAD (1.82 [95% CI 1.53, 2.18]) respectively were not appreciably different (<italic>F</italic> = 2.13, <italic>p</italic> = 0.176). Similarly, there was no evidence of a systematic difference in RR estimates between studies with the outcome of CHD (1.62 [95% CI 1.43, 1.81]) compared to CVD (RR 1.79 [95% CI 1.36, 2.34]) (<italic>F</italic> = 0.38, <italic>p</italic> = 0.552). Further meta-regressions did not find consistent evidence that RR estimated differed by gender, geographic location, sample storage temperature, study date or follow-up period (data not presented). The RR for CVD among participants in the top third of IL-18 compared with the lowest third and adjusted for age, gender, lipids, BMI and behavioural risk factors corrected using the RDR of 0.71 was 1.53 (95% CI 1.37, 1.79).</p>
      </sec>
    </sec>
    <sec id="sec0050">
      <label>3</label>
      <title>Discussion</title>
      <p>In this large population-based prospective study among mainly healthy middle-aged men, baseline circulating IL-18 concentrations were positively associated with CHD risk. Once conventional vascular risk factors were accounted for, the strength of the independent relationship was modest, with CHD risk in the highest third of the IL-18 distribution being approximately 30% higher than that in the lowest third. Positive associations between IL-18 and CHD are consistent with its postulated role in atherosclerotic plaque progression and rupture <xref rid="bib0030 bib0035" ref-type="bibr">[6,7]</xref>. IL-18 is an important regulator of both innate and acquired immune responses <xref rid="bib0025" ref-type="bibr">[5]</xref>. It is present in human atherosclerotic lesions, and at higher concentrations in unstable plaques <xref rid="bib0030" ref-type="bibr">[6]</xref>. In animal models, IL-18 administration leads to increases in atherosclerotic lesion size and promotes increased numbers of T-lymphocytes in the lesion <xref rid="bib0155" ref-type="bibr">[31]</xref>, suggesting that it may be of pathogenic importance in the tissue. We show that elevated IL-18 is associated with increased CVD risk, but whether this observation is indicative of IL-18 being causal in plaque rupture, or whether rupture prone plaques “leak” IL-18 into the circulation (reverse causality), or the association is coincidental, is currently unknown.</p>
      <p>In addition to providing the largest prospective study of IL-18 and CHD risk reported to date (with almost twice as many CHD cases as the next largest study), the meta-analysis results, based on data from all published prospective studies, suggest that there is an independent association between IL-18 and CHD risk, independent of classical risk factors, with higher risk consistently observed in all studies. The effect is maintained even after adjustment for both established cardiovascular risk markers and for inflammatory markers. In the BRHS data the association of IL-18 with incident CHD was not significant after adjustment for CRP and IL-6, although CRP remained an independent predictor of CHD suggesting separate pathways from CRP and IL-18 to CHD risk. The RR adjusted for other inflammatory markers was of the order of 35% in the meta-analysis, so the strength of association with CHD is slightly smaller than that estimated for CRP in a recent meta-analysis, similar to that for erythrocyte sedimentation rate and stronger than that for von Willebrand factor <xref rid="bib0015" ref-type="bibr">[3]</xref>. However it is possible that intra-individual variability of IL-18 could lead to under-estimation of the strength of its association with CHD risk, as previously reported for IL-6 <xref rid="bib0020" ref-type="bibr">[4]</xref>. We report, for the first time, a serial study of IL-18 measurements over 4 years, and use this data to correct for regression dilution bias. The RDR-corrected RR adjusted for established risk factors from the meta-analysis strengthened somewhat from 1.35 to 1.53 (95% CI 1.37, 1.79); more similar to the magnitude of the uncorrected adjusted association of CRP with CHD <xref rid="bib0015" ref-type="bibr">[3]</xref>.</p>
      <p>However, in the present study population, after adjustment for established risk factors the strength of the association between IL-18 and CHD was weaker than both the associations with other established risk factors such as blood pressure and cholesterol <xref rid="bib0160" ref-type="bibr">[32]</xref>, and the associations of other inflammatory markers <xref rid="bib0020 bib0075" ref-type="bibr">[4,15]</xref>. These results therefore provide little support for the value of IL-18 as a predictor of risk in individual subjects. In the north Glasgow MONICA cohort study (included in the meta-analysis), IL-18 added less than 0.1% to the prediction of CVD using the ASSIGN risk score, once standard CVD risk factors and social class were accounted for. They also reported that CRP, a marker consistently associated with CVD events, did add to the prediction of CVD risk, although other studies have found moderate or little evidence for additional value of inflammatory markers as predictors of individual risk <xref rid="bib0135" ref-type="bibr">[27]</xref>. Nevertheless, IL-18 is still of potential interest as a causal factor in CHD, and potentially as a therapeutic target. In addition to testing of causality by Mendelian randomization studies <xref rid="bib0145" ref-type="bibr">[29]</xref>, any trials of potential IL-18 antagonists would be of interest although we know of no such drugs currently in clinical trials.</p>
      <p>Variation within the <italic>IL18</italic> gene has been shown to influence circulating levels of IL-18 in both association studies <xref rid="bib0065 bib0165 bib0170" ref-type="bibr">[13,33,34]</xref>, and in a genome wide association study <xref rid="bib0175" ref-type="bibr">[35]</xref>. These SNPs have been reported to be associated with clinical outcome in subjects with coronary artery disease <xref rid="bib0145 bib0230 bib0180" ref-type="bibr">[29,36,37]</xref> but this is not seen in all studies <xref rid="bib0185 bib0190" ref-type="bibr">[38,39]</xref>. <italic>IL18</italic> SNPs also are associated with differences in IL-18 production capability by monocytes <xref rid="bib0195 bib0200 bib0205" ref-type="bibr">[40–42]</xref>. While single SNPs in the gene are associated with modest effect on plasma levels, several groups have demonstrated that certain haplotypes defined by up to five SNPs in combination are strongly associated with lower levels of serum IL-18 in healthy individuals where for example subjects carrying two copies of the haplotype had IL-18 concentrations 15–20% lower than those carrying no copies <xref rid="bib0065 bib0165" ref-type="bibr">[13,33]</xref>, and with lower levels of serum IL-18 in individuals with cardiovascular disease, and with protection from future cardiovascular events <xref rid="bib0145" ref-type="bibr">[29]</xref>. No non-synonymous variation has been identified in <italic>IL18</italic> despite exon sequencing in a number of individuals. It is therefore likely that the functional polymorphism(s) responsible for these observed associations cause differences in promoter activity, mRNA splicing or mRNA stability, but the precise mechanism is currently unknown.</p>
      <p>It would therefore be possible to use <italic>IL18</italic> genotypes to distinguish association and causation using a Mendelian randomization approach, as has previously been done for CRP <xref rid="bib0210" ref-type="bibr">[43]</xref> and fibrinogen <xref rid="bib0215" ref-type="bibr">[44]</xref>, suggesting that these factors are not causally related to CHD. Future studies could also examine whether effect modifiers of any associations between IL-18 and CHD; previous studies have demonstrated interactions between IL-18 or <italic>IL-18</italic> genotypes and factors related to CHD risk (e.g. metabolic syndrome <xref rid="bib0150" ref-type="bibr">[30]</xref>, hypertension <xref rid="bib0220" ref-type="bibr">[45]</xref> or cigarette smoking <xref rid="bib0225" ref-type="bibr">[46]</xref>), any such interactions could change the predictive value of circulating IL-18 levels.</p>
      <p>Compared with previous reports on IL-18, the present community-based study has considerably more CHD events and includes measurements of a wide range of potential confounding factors at study entry. For the first time, we report a meta-analysis of published studies and the potential impact of regression dilution bias. This study, like most others, is limited by having only a single measure of IL-18. However we estimated the intra-individual variability in serum IL-18 levels in a separate sub-study of men measured four years apart. Estimates suggested that the stability of serum IL-18 is similar to several established risk factors e.g. total cholesterol <xref rid="bib0125" ref-type="bibr">[25]</xref> and correction for within-person variability, somewhat strengthened the estimated associations with CHD or CVD. Despite prolonged sample storage before measurements (approximately 24 years at −20 °C, which was suboptimal for such a long time span), which might have resulted in underestimation of the association of IL-18 with CHD, the validity of our IL-18 levels is supported by their consistency with those in previously reported studies <xref rid="bib0055 bib0060" ref-type="bibr">[11,12]</xref>, by their associations with independently assessed inflammatory markers and by the consistency of the findings with those of the previously published prospective studies. The meta-analysis of prospective studies included data from all studies identified from three major databases and provided no strong evidence for small study bias. Additionally, sensitivity analyses excluding studies with CVD rather than CHD endpoints and based in high risk rather than general populations did not alter our conclusions. While the analysis of British Regional Heart Study data included only men, nine of the twelve studies in the meta-analysis included women, so our conclusions about the associations between IL-18 and CVD events are generalised to both men and women.</p>
    </sec>
    <sec id="sec0055">
      <label>4</label>
      <title>Conclusions</title>
      <p>The results of the present study and the meta-analysis suggest that IL-18 is prospectively and independently associated with CHD risk, but the association is modest in strength.</p>
    </sec>
    <sec id="sec0060">
      <title>Conflict of interest</title>
      <p>The authors have no conflict of interest to declare.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib0005">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ross</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Atherosclerosis – an inflammatory disease</article-title>
          <source>N Engl J Med</source>
          <volume>340</volume>
          <year>1999</year>
          <fpage>115</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">9887164</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lewington</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>S.G.</given-names>
            </name>
          </person-group>
          <article-title>Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis</article-title>
          <source>JAMA</source>
          <volume>294</volume>
          <year>2005</year>
          <fpage>1799</fpage>
          <lpage>1809</lpage>
          <pub-id pub-id-type="pmid">16219884</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Wheeler</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>Hirschfield</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease</article-title>
          <source>N Engl J Med</source>
          <volume>350</volume>
          <year>2004</year>
          <fpage>1387</fpage>
          <lpage>1397</lpage>
          <pub-id pub-id-type="pmid">15070788</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Kaptoge</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review</article-title>
          <source>PLoS Med</source>
          <volume>5</volume>
          <year>2008</year>
          <fpage>e78</fpage>
          <pub-id pub-id-type="pmid">18399716</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gracie</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>McInnes</surname>
              <given-names>I.B.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-18</article-title>
          <source>J Leukoc Biol</source>
          <volume>73</volume>
          <year>2003</year>
          <fpage>213</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">12554798</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mallat</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Corbaz</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Scoazec</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability</article-title>
          <source>Circulation</source>
          <volume>104</volume>
          <year>2001</year>
          <fpage>1598</fpage>
          <lpage>1603</lpage>
          <pub-id pub-id-type="pmid">11581135</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0035">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerdes</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Sukhova</surname>
              <given-names>G.K.</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis</article-title>
          <source>J Exp Med</source>
          <volume>195</volume>
          <year>2002</year>
          <fpage>245</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="pmid">11805151</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blankenberg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tiret</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bickel</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina</article-title>
          <source>Circulation</source>
          <volume>106</volume>
          <year>2002</year>
          <fpage>24</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">12093765</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0045">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blankenberg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>McQueen</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Smieja</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study</article-title>
          <source>Circulation</source>
          <volume>114</volume>
          <year>2006</year>
          <fpage>201</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="pmid">16831981</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0050">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tziakas</surname>
              <given-names>D.N.</given-names>
            </name>
            <name>
              <surname>Chalikias</surname>
              <given-names>G.K.</given-names>
            </name>
            <name>
              <surname>Kaski</surname>
              <given-names>J.C.</given-names>
            </name>
          </person-group>
          <article-title>Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach</article-title>
          <source>Atherosclerosis</source>
          <volume>193</volume>
          <year>2007</year>
          <fpage>196</fpage>
          <lpage>203</lpage>
          <pub-id pub-id-type="pmid">16857204</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0055">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blankenberg</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Luc</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ducimetiere</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME)</article-title>
          <source>Circulation</source>
          <volume>108</volume>
          <year>2003</year>
          <fpage>2453</fpage>
          <lpage>2459</lpage>
          <pub-id pub-id-type="pmid">14581397</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0060">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hung</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Knuiman</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Divitini</surname>
              <given-names>M.L.</given-names>
            </name>
          </person-group>
          <article-title>C-reactive protein and interleukin-18 levels in relation to coronary heart disease: prospective cohort study from Busselton Western Australia</article-title>
          <source>Heart Lung Circ</source>
          <volume>17</volume>
          <year>2008</year>
          <fpage>90</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="pmid">17851127</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0065">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>Novick</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Stock</surname>
              <given-names>C.J.</given-names>
            </name>
          </person-group>
          <article-title>Free interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>27</volume>
          <year>2007</year>
          <fpage>2743</fpage>
          <lpage>2749</lpage>
          <pub-id pub-id-type="pmid">17951325</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0070">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Everett</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Bansal</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rifai</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Buring</surname>
              <given-names>J.E.</given-names>
            </name>
            <name>
              <surname>Ridker</surname>
              <given-names>P.M.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-18 and the risk of future cardiovascular disease among initially healthy women</article-title>
          <source>Atherosclerosis</source>
          <volume>202</volume>
          <year>2009</year>
          <fpage>282</fpage>
          <lpage>288</lpage>
          <pub-id pub-id-type="pmid">18514203</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0075">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Whincup</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses</article-title>
          <source>BMJ</source>
          <volume>321</volume>
          <year>2000</year>
          <fpage>199</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">10903648</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0080">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shaper</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Pocock</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns</article-title>
          <source>Br Med J (Clin Res Ed)</source>
          <volume>283</volume>
          <year>1981</year>
          <fpage>179</fpage>
          <lpage>186</lpage>
        </element-citation>
      </ref>
      <ref id="bib0085">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Whincup</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Shaper</surname>
              <given-names>A.G.</given-names>
            </name>
          </person-group>
          <article-title>The British Regional Heart Study 1975–2004</article-title>
          <source>Int J Epidemiol</source>
          <volume>33</volume>
          <year>2004</year>
          <fpage>1185</fpage>
          <lpage>1192</lpage>
          <pub-id pub-id-type="pmid">15319395</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0090">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Malik</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Whincup</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis</article-title>
          <source>Lancet</source>
          <volume>358</volume>
          <year>2001</year>
          <fpage>971</fpage>
          <lpage>976</lpage>
          <pub-id pub-id-type="pmid">11583751</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0095">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Whincup</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis</article-title>
          <source>Circulation</source>
          <volume>103</volume>
          <year>2001</year>
          <fpage>2323</fpage>
          <lpage>2327</lpage>
          <pub-id pub-id-type="pmid">11352877</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0100">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lowe</surname>
              <given-names>G.D.</given-names>
            </name>
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lewington</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis</article-title>
          <source>Eur Heart J</source>
          <volume>25</volume>
          <year>2004</year>
          <fpage>252</fpage>
          <lpage>259</lpage>
          <pub-id pub-id-type="pmid">14972427</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0105">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whincup</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Danesh</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>von Willebrand factor and coronary heart disease: prospective study and meta-analysis</article-title>
          <source>Eur Heart J</source>
          <volume>23</volume>
          <year>2002</year>
          <fpage>1764</fpage>
          <lpage>1770</lpage>
          <pub-id pub-id-type="pmid">12419296</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0110">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosner</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Spiegelman</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Willett</surname>
              <given-names>W.C.</given-names>
            </name>
          </person-group>
          <article-title>Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error</article-title>
          <source>Am J Epidemiol</source>
          <volume>136</volume>
          <year>1992</year>
          <fpage>1400</fpage>
          <lpage>1413</lpage>
          <pub-id pub-id-type="pmid">1488967</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0115">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Begg</surname>
              <given-names>C.B.</given-names>
            </name>
            <name>
              <surname>Mazumdar</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>
          <source>Biometrics</source>
          <volume>50</volume>
          <year>1994</year>
          <fpage>1088</fpage>
          <lpage>1101</lpage>
          <pub-id pub-id-type="pmid">7786990</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0120">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Davey</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Minder</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>
          <source>BMJ</source>
          <volume>315</volume>
          <year>1997</year>
          <fpage>629</fpage>
          <lpage>634</lpage>
          <pub-id pub-id-type="pmid">9310563</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0125">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emberson</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Whincup</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>R.W.</given-names>
            </name>
          </person-group>
          <article-title>Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study</article-title>
          <source>Eur J Cardiovasc Prev Rehabil</source>
          <volume>11</volume>
          <year>2004</year>
          <fpage>125</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="pmid">15187816</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0130">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Koenig</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Khuseyinova</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Baumert</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>26</volume>
          <year>2006</year>
          <fpage>2745</fpage>
          <lpage>2751</lpage>
          <pub-id pub-id-type="pmid">17008587</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0135">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Woodward</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Welsh</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rumley</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tunstall-Pedoe</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results from a 10 year cohort study in Glasgow, Scotland</article-title>
          <source>Eur Heart J</source>
          <volume>31</volume>
          <year>2010</year>
          <fpage>2669</fpage>
          <lpage>2675</lpage>
          <pub-id pub-id-type="pmid">19363058</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0140">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Welsh</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Woodward</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Rumley</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>MacMahon</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lowe</surname>
              <given-names>G.D.</given-names>
            </name>
          </person-group>
          <article-title>Does interleukin-18 or tumour necrosis factor-a have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand</article-title>
          <source>Cytokine</source>
          <volume>50</volume>
          <year>2010</year>
          <fpage>94</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">20096599</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0145">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tiret</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Godefroy</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lubos</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease</article-title>
          <source>Circulation</source>
          <volume>112</volume>
          <year>2005</year>
          <fpage>643</fpage>
          <lpage>650</lpage>
          <pub-id pub-id-type="pmid">16043644</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0150">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Troseid</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Seljeflot</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Hjerkinn</surname>
              <given-names>E.M.</given-names>
            </name>
            <name>
              <surname>Arnesen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia</article-title>
          <source>Diabetes Care</source>
          <volume>32</volume>
          <year>2009</year>
          <fpage>486</fpage>
          <lpage>492</lpage>
          <pub-id pub-id-type="pmid">19092166</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0155">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitman</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Ravisankar</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Daugherty</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin-18 enhances atherosclerosis in apolipoprotein E(−/−) mice through release of interferon-gamma</article-title>
          <source>Circ Res</source>
          <volume>90</volume>
          <year>2002</year>
          <fpage>E34</fpage>
          <lpage>E38</lpage>
          <pub-id pub-id-type="pmid">11834721</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0160">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emberson</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Whincup</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Morris</surname>
              <given-names>R.W.</given-names>
            </name>
            <name>
              <surname>Walker</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias</article-title>
          <source>Eur Heart J</source>
          <volume>24</volume>
          <year>2003</year>
          <fpage>1719</fpage>
          <lpage>1726</lpage>
          <pub-id pub-id-type="pmid">14522566</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0165">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>S.R.</given-names>
            </name>
            <name>
              <surname>McCaskie</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Beilby</surname>
              <given-names>J.P.</given-names>
            </name>
          </person-group>
          <article-title>IL18 haplotypes are associated with serum IL-18 concentrations in a population-based study and a cohort of individuals with premature coronary heart disease</article-title>
          <source>Clin Chem</source>
          <volume>53</volume>
          <year>2007</year>
          <fpage>2078</fpage>
          <lpage>2085</lpage>
          <pub-id pub-id-type="pmid">17962365</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0170">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Presta</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Andreozzi</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Succurro</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>IL-18 gene polymorphism and metabolic syndrome</article-title>
          <source>Nutr Metab Cardiovasc Dis</source>
          <volume>19</volume>
          <year>2009</year>
          <fpage>e5</fpage>
          <lpage>e6</lpage>
          <pub-id pub-id-type="pmid">19176284</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0175">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease</article-title>
          <source>Angiology</source>
          <volume>60</volume>
          <year>2009</year>
          <fpage>180</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">18599493</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0230">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>He</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Cornelis</surname>
              <given-names>M.C.</given-names>
            </name>
            <name>
              <surname>Kraft</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels</article-title>
          <source>Arterioscler Thromb Vasc Biol</source>
          <volume>30</volume>
          <year>2010</year>
          <fpage>885</fpage>
          <lpage>890</lpage>
          <pub-id pub-id-type="pmid">20150558</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0180">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pei</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>Association of interleukin-18 gene promoter polymorphisms with risk of acute myocardial infarction in northern Chinese Han population</article-title>
          <source>Clin Chem Lab Med</source>
          <volume>47</volume>
          <year>2009</year>
          <fpage>523</fpage>
          <lpage>529</lpage>
          <pub-id pub-id-type="pmid">19309308</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0185">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grisoni</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Proust</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Alanne</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Lack of association between polymorphisms of the IL18R1 and IL18RAP genes and cardiovascular risk: the MORGAM Project</article-title>
          <source>BMC Med Genet</source>
          <volume>10</volume>
          <year>2009</year>
          <fpage>44</fpage>
          <pub-id pub-id-type="pmid">19473509</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0190">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hernesniemi</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Anttila</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nieminen</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>IL-18 gene polymorphism, cardiovascular mortality and coronary artery disease</article-title>
          <source>Eur J Clin Invest</source>
          <volume>40</volume>
          <year>2010</year>
          <fpage>994</fpage>
          <lpage>1001</lpage>
          <pub-id pub-id-type="pmid">20735470</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0195">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arimitsu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Higa</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>IL-18 gene polymorphisms affect IL-18 production capability by monocytes</article-title>
          <source>Biochem Biophys Res Commun</source>
          <volume>342</volume>
          <year>2006</year>
          <fpage>1413</fpage>
          <lpage>1416</lpage>
          <pub-id pub-id-type="pmid">16516851</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0200">
        <label>41</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barbaux</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Poirier</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Godefroy</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Differential haplotypic expression of the interleukin-18 gene</article-title>
          <source>Eur J Hum Genet</source>
          <volume>15</volume>
          <year>2007</year>
          <fpage>856</fpage>
          <lpage>863</lpage>
          <pub-id pub-id-type="pmid">17487222</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0205">
        <label>42</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khripko</surname>
              <given-names>O.P.</given-names>
            </name>
            <name>
              <surname>Sennikova</surname>
              <given-names>N.S.</given-names>
            </name>
            <name>
              <surname>Lopatnikova</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors</article-title>
          <source>Mediators Inflamm</source>
          <volume>2008</volume>
          <year>2008</year>
          <fpage>309721</fpage>
          <pub-id pub-id-type="pmid">18949051</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0210">
        <label>43</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casas</surname>
              <given-names>J.P.</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Cooper</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Insight into the nature of the CRP-coronary event association using Mendelian randomization</article-title>
          <source>Int J Epidemiol</source>
          <volume>35</volume>
          <year>2006</year>
          <fpage>922</fpage>
          <lpage>931</lpage>
          <pub-id pub-id-type="pmid">16565153</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0215">
        <label>44</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davey</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Harbord</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Ebrahim</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Fibrinogen C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal?</article-title>
          <source>QJM</source>
          <volume>97</volume>
          <year>2004</year>
          <fpage>163</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">14976273</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0220">
        <label>45</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grisoni</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Proust</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Alanne</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Haplotypic analysis of tag SNPs of the interleukin-18 gene in relation to cardiovascular disease events: the MORGAM Project</article-title>
          <source>Eur J Hum Genet</source>
          <volume>16</volume>
          <year>2008</year>
          <fpage>1512</fpage>
          <lpage>1520</lpage>
          <pub-id pub-id-type="pmid">18628791</pub-id>
        </element-citation>
      </ref>
      <ref id="bib0225">
        <label>46</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hernesniemi</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Karhunen</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Oksala</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study</article-title>
          <source>Eur Heart J</source>
          <volume>30</volume>
          <year>2009</year>
          <fpage>2939</fpage>
          <lpage>2946</lpage>
          <pub-id pub-id-type="pmid">19687159</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="sec0070" sec-type="supplementary-material">
      <label>Appendix A</label>
      <title>Supplementary data</title>
      <p>
        <supplementary-material content-type="local-data" id="upi0005">
          <media xlink:href="mmc1.doc" mimetype="application" mime-subtype="msword"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgments</title>
      <p>We are very grateful to the following individuals for providing data in the format required for the meta-analysis for each study. Atherogene: S.Blankenberg, L.Tiret; PRIME: P. Ducimetière, S. Blankenberg, L. Tiret; HOPE: S. Blankenberg, L. Tiret; KORA/Augsberg: W. Koenig, B. Khuseyinova; NPHSII: S. Thompson, J. Cooper; Busselton: J. Hung, M. Knuiman; Greek case series: D. Tziakas, G. Chalikias, J.C. Kaski; 4th Glasgow MONICA: H. Tunstall Pedoe; Women's Health Study, B.M. Everett, P.M. Ridker; OSLO, M. Trøseid, I. Seljeflot and H. Arnesen.</p>
      <p>This work was supported by the British Heart Foundation: Professor AG Shaper established the British Regional Heart Study, which is a British Heart Foundation Research Group. PHW, AR, GDOL and SEH are supported by programme grants from the British Heart Foundation [grants RG/04/003, RG/08/013/25942 and RG/08/008]. The views expressed in this paper are those of the authors and not necessarily those of the British Heart Foundation.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig0005">
      <label>Fig. 1</label>
      <caption>
        <p>Associations of baseline IL-18 level and risk of onset of CHD in 12 studies, adjusted for age and gender. Models ordered by statistical weight.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <table-wrap id="tbl0005" position="float">
      <label>Table 1</label>
      <caption>
        <p>Baseline characteristics of men with coronary heart disease and of age and town-matched controls. Mean (SD) or <italic>n</italic> (%).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th align="left">Cases</th>
            <th align="left">Controls</th>
            <th align="left"><italic>p</italic> (no difference)</th>
          </tr>
          <tr>
            <th/>
            <th align="left">(<italic>n</italic> = 595)</th>
            <th align="left">(<italic>n</italic> = 1238)</th>
            <th/>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Age (years)</td>
            <td align="left">52.6 (5.2)</td>
            <td align="left">52.5 (5.3)</td>
            <td align="left">Matched</td>
          </tr>
          <tr>
            <td align="left">Current smoker (<italic>n</italic>, %)</td>
            <td align="left">304 (51.2)</td>
            <td align="left">521 (42.2)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Evidence of coronary disease (<italic>n</italic>, %)</td>
            <td align="left">247 (41.5)</td>
            <td align="left">327 (26.4)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">History of diabetes (<italic>n</italic>, %)</td>
            <td align="left">16 (2.7)</td>
            <td align="left">18 (1.5)</td>
            <td align="left">0.091</td>
          </tr>
          <tr>
            <td align="left">&gt;2 drinks alcohol/day (<italic>n</italic>, %)</td>
            <td align="left">120 (20.2)</td>
            <td align="left">278 (22.5)</td>
            <td align="left">0.262</td>
          </tr>
          <tr>
            <td align="left">Non-manual occupation (<italic>n</italic>, %)</td>
            <td align="left">184 (32.3)</td>
            <td align="left">465 (38.7)</td>
            <td align="left">0.009</td>
          </tr>
          <tr>
            <td align="left">Physical activity (inactive/occasional) (<italic>n</italic>, %)</td>
            <td align="left">275(46.7)</td>
            <td align="left">493(40.4)</td>
            <td align="left">0.011</td>
          </tr>
          <tr>
            <td colspan="4" align="left">
              <bold>Physical measurements</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Body mass index (kg/m<sup>2</sup>)</td>
            <td align="left">25.9 (3.4)</td>
            <td align="left">25.4 (3.3)</td>
            <td align="left">0.001</td>
          </tr>
          <tr>
            <td align="left">Systolic blood pressure (mm Hg)</td>
            <td align="left">151.8 (21.8)</td>
            <td align="left">146.7 (20.9)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Diastolic blood pressure (mm Hg)</td>
            <td align="left">85.7 (13.8)</td>
            <td align="left">82.8 (13.2)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">FEV<sub>1</sub> (L/min)<xref rid="tblfn0005" ref-type="table-fn">a</xref></td>
            <td align="left">3.10 (0.65)</td>
            <td align="left">3.21 (0.71)</td>
            <td align="left">0.002</td>
          </tr>
          <tr>
            <td align="left">Blood sample</td>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td align="left">Total cholesterol (mmol/L)</td>
            <td align="left">6.64 (1.06)</td>
            <td align="left">6.20 (0.99)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">HDL cholesterol (mmol/L)</td>
            <td align="left">1.09 (0.27)</td>
            <td align="left">1.15 (0.27)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Triglyceride (mmol/L)<xref rid="tblfn0010" ref-type="table-fn">b</xref></td>
            <td align="left">1.95 (0.69, 5.51)</td>
            <td align="left">1.70 (0.57, 5.02)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">IL-18 (pg/mL)<xref rid="tblfn0010" ref-type="table-fn">b</xref></td>
            <td align="left">302.0 (117.1, 779.1)</td>
            <td align="left">275.4 (106.8, 710.6)</td>
            <td align="left">0.001</td>
          </tr>
          <tr>
            <td align="left">C-reactive protein (mg/L)<xref rid="tblfn0010" ref-type="table-fn">b</xref></td>
            <td align="left">2.51 (0.30, 20.95)</td>
            <td align="left">1.45 (0.14, 15.11)</td>
            <td align="left">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">IL-6 (pg/mL)<xref rid="tblfn0010" ref-type="table-fn">b</xref></td>
            <td align="left">2.75 (0.81, 9.32)</td>
            <td align="left">2.29 (0.65, 8.11)</td>
            <td align="left">&lt;0.001</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tblfn0005">
          <label>a</label>
          <p>FEV<sub>1</sub> adjusted for [(cohort mean height)<sup>2</sup>/height<sup>2</sup>].</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0010">
          <label>b</label>
          <p>Geometric mean and 95% range.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl0010" position="float">
      <label>Table 2</label>
      <caption>
        <p>Association between IL-18 (thirds) and cardiovascular risk factors in the coronary heart disease control sample (<italic>n</italic> = 1237).</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th colspan="7" align="left">Thirds of IL-18<hr/></th>
          </tr>
          <tr>
            <th/>
            <th colspan="2" align="left">Low 29–233 pg/mL (<italic>n</italic> = 411)<hr/></th>
            <th colspan="2" align="left">Middle 234–345 pg/mL (<italic>n</italic> = 413)<hr/></th>
            <th colspan="2" align="left">High 346–2068 pg/mL (<italic>n</italic> = 414)<hr/></th>
            <th align="left"><italic>p</italic> (trend), adjusted for age and town</th>
          </tr>
          <tr>
            <th/>
            <th align="left">Mean or n</th>
            <th align="left">SE or %</th>
            <th align="left">Mean or n</th>
            <th align="left">SE or %</th>
            <th align="left">Mean or n</th>
            <th align="left">SE or %</th>
            <th/>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Age</td>
            <td align="char">52.5</td>
            <td align="char">0.3</td>
            <td align="char">52.1</td>
            <td align="char">0.3</td>
            <td align="char">52.8</td>
            <td align="char">0.3</td>
            <td align="char">0.609</td>
          </tr>
          <tr>
            <td align="left">Current smoker (<italic>n</italic>, %)</td>
            <td align="char">133</td>
            <td align="char">32.4</td>
            <td align="char">188</td>
            <td align="char">45.7</td>
            <td align="char">200</td>
            <td align="char">48.3</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">&gt;2 drinks alcohol/day (<italic>n</italic>, %)</td>
            <td align="char">98</td>
            <td align="char">23.8</td>
            <td align="char">86</td>
            <td align="char">20.9</td>
            <td align="char">94</td>
            <td align="char">22.7</td>
            <td align="char">0.558</td>
          </tr>
          <tr>
            <td align="left">Evidence of CHD at entry (<italic>n</italic>, %)</td>
            <td align="char">106</td>
            <td align="char">25.8</td>
            <td align="char">113</td>
            <td align="char">27.4</td>
            <td align="char">108</td>
            <td align="char">26.1</td>
            <td align="char">0.773</td>
          </tr>
          <tr>
            <td align="left">History of diabetes at baseline (<italic>n</italic>, %)</td>
            <td align="char">7</td>
            <td align="char">1.7</td>
            <td align="char">6</td>
            <td align="char">1.5</td>
            <td align="char">6</td>
            <td align="char">1.5</td>
            <td align="char">0.770</td>
          </tr>
          <tr>
            <td align="left">Non-manual occupations (<italic>n</italic>, %)</td>
            <td align="char">181</td>
            <td align="char">45.1</td>
            <td align="char">145</td>
            <td align="char">36.4</td>
            <td align="char">139</td>
            <td align="char">34.3</td>
            <td align="char">0.016</td>
          </tr>
          <tr>
            <td align="left">Physical Activity (inactive/occasional) (<italic>n</italic>, %)</td>
            <td align="char">152</td>
            <td align="char">37.7</td>
            <td align="char">169</td>
            <td align="char">41.6</td>
            <td align="char">172</td>
            <td align="char">41.8</td>
            <td align="char">0.656</td>
          </tr>
          <tr>
            <td align="left">Body mass index (kg/m<sup>2</sup>)</td>
            <td align="char">25.1</td>
            <td align="char">0.2</td>
            <td align="char">25.5</td>
            <td align="char">0.2</td>
            <td align="char">25.6</td>
            <td align="char">0.2</td>
            <td align="char">0.052</td>
          </tr>
          <tr>
            <td align="left">Systolic blood pressure (mm Hg)</td>
            <td align="char">144.6</td>
            <td align="char">1.0</td>
            <td align="char">146.9</td>
            <td align="char">1.0</td>
            <td align="char">148.4</td>
            <td align="char">1.0</td>
            <td align="char">0.033</td>
          </tr>
          <tr>
            <td align="left">Diastolic blood pressure (mm Hg)</td>
            <td align="char">81.0</td>
            <td align="char">0.6</td>
            <td align="char">83.8</td>
            <td align="char">0.6</td>
            <td align="char">83.4</td>
            <td align="char">0.6</td>
            <td align="char">0.018</td>
          </tr>
          <tr>
            <td align="left">FEV<sub>1</sub> [adjusted] (L/min)<xref rid="tblfn0015" ref-type="table-fn">a</xref></td>
            <td align="char">3.26</td>
            <td align="char">0.04</td>
            <td align="char">3.20</td>
            <td align="char">0.04</td>
            <td align="char">3.16</td>
            <td align="char">0.04</td>
            <td align="char">0.617</td>
          </tr>
          <tr>
            <td align="left">Total cholesterol (mmol/L)</td>
            <td align="char">6.14</td>
            <td align="char">0.05</td>
            <td align="char">6.23</td>
            <td align="char">0.05</td>
            <td align="char">6.21</td>
            <td align="char">0.05</td>
            <td align="char">0.394</td>
          </tr>
          <tr>
            <td align="left">HDL cholesterol (mmol/L)</td>
            <td align="char">1.20</td>
            <td align="char">0.01</td>
            <td align="char">1.15</td>
            <td align="char">0.01</td>
            <td align="char">1.11</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Triglycerides (mmol/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.19</td>
            <td align="char">0.01</td>
            <td align="char">0.22</td>
            <td align="char">0.01</td>
            <td align="char">0.26</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Haematocrit (%)</td>
            <td align="char">41.91</td>
            <td align="char">0.45</td>
            <td align="char">42.79</td>
            <td align="char">0.45</td>
            <td align="char">42.45</td>
            <td align="char">0.45</td>
            <td align="char">0.700</td>
          </tr>
          <tr>
            <td align="left">Homocysteine (mmol/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">1.10</td>
            <td align="char">0.01</td>
            <td align="char">1.12</td>
            <td align="char">0.01</td>
            <td align="char">0.16</td>
            <td align="char">0.01</td>
            <td align="char">0.011</td>
          </tr>
          <tr>
            <td align="left">Insulin (mU/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">1.07</td>
            <td align="char">0.02</td>
            <td align="char">1.05</td>
            <td align="char">0.02</td>
            <td align="char">1.13</td>
            <td align="char">0.02</td>
            <td align="char">0.032</td>
          </tr>
          <tr>
            <td align="left">Glucose (mmol/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.74</td>
            <td align="char">0.004</td>
            <td align="char">0.74</td>
            <td align="char">0.004</td>
            <td align="char">0.74</td>
            <td align="char">0.004</td>
            <td align="char">0.690</td>
          </tr>
          <tr>
            <td align="left">C-reactive protein (mg/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.05</td>
            <td align="char">0.03</td>
            <td align="char">0.15</td>
            <td align="char">0.03</td>
            <td align="char">0.30</td>
            <td align="char">0.03</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Serum amyloid A protein (mg/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.81</td>
            <td align="char">0.02</td>
            <td align="char">0.83</td>
            <td align="char">0.02</td>
            <td align="char">0.88</td>
            <td align="char">0.02</td>
            <td align="char">0.003</td>
          </tr>
          <tr>
            <td align="left">White cell count (10<sup>9</sup>/L)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.83</td>
            <td align="char">0.01</td>
            <td align="char">0.85</td>
            <td align="char">0.01</td>
            <td align="char">0.85</td>
            <td align="char">0.01</td>
            <td align="char">0.011</td>
          </tr>
          <tr>
            <td align="left">Albumin (g/L)</td>
            <td align="char">44.7</td>
            <td align="char">0.1</td>
            <td align="char">44.6</td>
            <td align="char">0.1</td>
            <td align="char">44.3</td>
            <td align="char">0.1</td>
            <td align="char">0.003</td>
          </tr>
          <tr>
            <td align="left">Globulin (g/L)</td>
            <td align="char">28.9</td>
            <td align="char">0.2</td>
            <td align="char">28.9</td>
            <td align="char">0.2</td>
            <td align="char">29.3</td>
            <td align="char">0.2</td>
            <td align="char">0.101</td>
          </tr>
          <tr>
            <td align="left">E-selectin (ng/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">1.74</td>
            <td align="char">0.01</td>
            <td align="char">1.77</td>
            <td align="char">0.01</td>
            <td align="char">1.82</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">P-selectin (ng/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">2.00</td>
            <td align="char">0.01</td>
            <td align="char">2.01</td>
            <td align="char">0.01</td>
            <td align="char">2.07</td>
            <td align="char">0.01</td>
            <td align="char">0.001</td>
          </tr>
          <tr>
            <td align="left">ICAM 1 (ng/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">2.43</td>
            <td align="char">0.01</td>
            <td align="char">2.47</td>
            <td align="char">0.01</td>
            <td align="char">2.52</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">VCAM 1 (ng/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">2.62</td>
            <td align="char">0.01</td>
            <td align="char">2.64</td>
            <td align="char">0.01</td>
            <td align="char">2.66</td>
            <td align="char">0.01</td>
            <td align="char">0.008</td>
          </tr>
          <tr>
            <td align="left">von Willebrand factor (IU/dL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">2.00</td>
            <td align="char">0.01</td>
            <td align="char">2.01</td>
            <td align="char">0.01</td>
            <td align="char">2.05</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">Fibrin D-dimer (ng/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">1.86</td>
            <td align="char">0.02</td>
            <td align="char">1.88</td>
            <td align="char">0.02</td>
            <td align="char">1.93</td>
            <td align="char">0.02</td>
            <td align="char">0.008</td>
          </tr>
          <tr>
            <td align="left">t-PA (ng/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.97</td>
            <td align="char">0.01</td>
            <td align="char">1.01</td>
            <td align="char">0.01</td>
            <td align="char">1.06</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
          <tr>
            <td align="left">IL-6 (pg/mL)<xref rid="tblfn0020" ref-type="table-fn">b</xref></td>
            <td align="char">0.31</td>
            <td align="char">0.01</td>
            <td align="char">0.36</td>
            <td align="char">0.01</td>
            <td align="char">0.41</td>
            <td align="char">0.01</td>
            <td align="char">&lt;0.001</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tblfn0015">
          <label>a</label>
          <p>FEV adjusted for [(cohort mean height)<sup>2</sup>/height<sup>2</sup>].</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0020">
          <label>b</label>
          <p>Values are transformed to log base 10.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl0015" position="float">
      <label>Table 3</label>
      <caption>
        <p>Odds ratios for coronary heart disease in men by thirds of IL-18 and for continuous (doubling of) IL-18.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left">IL-18 values</th>
            <th align="left">Cases</th>
            <th align="left">Controls</th>
            <th colspan="4" align="left">OR (95% CI)<hr/></th>
          </tr>
          <tr>
            <th align="left">Thirds</th>
            <th align="left">
              <italic>N</italic>
            </th>
            <th align="left">
              <italic>N</italic>
            </th>
            <th align="left">Model 1<xref rid="tblfn0025" ref-type="table-fn">a</xref></th>
            <th align="left">Model 2<xref rid="tblfn0030" ref-type="table-fn">b</xref></th>
            <th align="left">Model 3<xref rid="tblfn0035" ref-type="table-fn">c</xref></th>
            <th align="left">Model 4<xref rid="tblfn0040" ref-type="table-fn">d</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="7" align="left"><bold>All participants,</bold><italic><bold>n</bold></italic> <bold>=</bold> <bold>1833</bold> (range pg/mL)</td>
          </tr>
          <tr>
            <td align="left">346–2068</td>
            <td align="char">242</td>
            <td align="char">414</td>
            <td align="left">1.55 (1.21, 1.98)</td>
            <td align="left">1.48(1.15, 1.90)</td>
            <td align="left">1.30 (0.99, 1.69)</td>
            <td align="left">1.12 (0.84, 1.49)</td>
          </tr>
          <tr>
            <td align="left">234–345</td>
            <td align="char">193</td>
            <td align="char">413</td>
            <td align="left">1.24 (0.96, 1.59)</td>
            <td align="left">1.19 (0.92, 1.54)</td>
            <td align="left">1.06 (0.81, 1.39)</td>
            <td align="left">1.04 (0.78, 1.38)</td>
          </tr>
          <tr>
            <td align="left">29–233</td>
            <td align="char">160</td>
            <td align="char">411</td>
            <td align="left">1</td>
            <td align="left">1</td>
            <td align="left">1</td>
            <td align="left">1</td>
          </tr>
          <tr>
            <td align="left">Total</td>
            <td align="char">595</td>
            <td align="char">1238</td>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td align="left">Continuous doubling of IL-18<xref rid="tblfn0045" ref-type="table-fn">e</xref></td>
            <td/>
            <td/>
            <td align="left">1.30(1.12,1.50)</td>
            <td align="left">1.23(1.09, 1.47)</td>
            <td align="left">1.21(1.03, 1.42)</td>
            <td align="left">1.14(0.96, 1.34)</td>
          </tr>
          <tr>
            <td align="left"><italic>p</italic> trend<xref rid="tblfn0045" ref-type="table-fn">e</xref></td>
            <td/>
            <td/>
            <td align="left">0.003</td>
            <td align="left">0.008</td>
            <td align="left">0.032</td>
            <td align="left">0.191</td>
          </tr>
          <tr>
            <td colspan="7" align="left"><bold>Participants without baseline CHD (BRHS definition),</bold><italic><bold>n</bold></italic> <bold>=</bold> <bold>1259</bold> (range pg/mL)</td>
          </tr>
          <tr>
            <td align="left">346–2068</td>
            <td align="char">150</td>
            <td align="char">306</td>
            <td align="left">1.63 (1.19 2.22)</td>
            <td align="left">1.53 (1.12, 2.10)</td>
            <td align="left">1.29 (0.92, 1.80)</td>
            <td align="left">1.11 (0.77, 1.50)</td>
          </tr>
          <tr>
            <td align="left">234–345</td>
            <td align="char">105</td>
            <td align="char">300</td>
            <td align="left">1.16 (0.84 1.60)</td>
            <td align="left">1.09 (0.79, 1.52)</td>
            <td align="left">1.03 (0.73, 1.46)</td>
            <td align="left">1.05 (0.73, 1.51)</td>
          </tr>
          <tr>
            <td align="left">47–233</td>
            <td align="char">93</td>
            <td align="char">305</td>
            <td align="left">1</td>
            <td align="left">1</td>
            <td align="left">1</td>
            <td align="left">1</td>
          </tr>
          <tr>
            <td align="left">Total</td>
            <td align="char">348</td>
            <td align="char">911</td>
            <td/>
            <td/>
            <td/>
            <td/>
          </tr>
          <tr>
            <td align="left">Continuous doubling of IL-18<xref rid="tblfn0045" ref-type="table-fn">e</xref></td>
            <td/>
            <td/>
            <td align="left">1.31 (1.09, 1.57)</td>
            <td align="left">1.27 (1.06, 1.53)</td>
            <td align="left">1.16 (0.95, 1.41)</td>
            <td align="left">1.09 (0.88, 1.35)</td>
          </tr>
          <tr>
            <td align="left"><italic>p</italic> trend<xref rid="tblfn0045" ref-type="table-fn">e</xref></td>
            <td/>
            <td/>
            <td align="left">0.030</td>
            <td align="left">0.056</td>
            <td align="left">0.343</td>
            <td align="left">0.758</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tblfn0025">
          <label>a</label>
          <p>Model 1 = age + town.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0030">
          <label>b</label>
          <p>Model 2 = Model 1 + smoking.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0035">
          <label>c</label>
          <p>Model 3 = Model 2 + blood pressure, total cholesterol, HDL, body mass index, history of diabetes, CHD, social class, physical activity.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0040">
          <label>d</label>
          <p>Model 4 = Model 3 + log<sub>10</sub> C-reactive protein (mg/L), log<sub>10</sub> IL-6 (pg/mL).</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn0045">
          <label>e</label>
          <p>OR of MI per 1 log<sub>2</sub> increase in log<sub>2</sub>(IL-18), i.e. a doubling of IL-18, <italic>p</italic> value for trend using IL-18 as a continuous variable.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>